Biochemical Engineering Special Interest Group
biological engineering professionals
26 September 2016

Adaptimmune and MD Anderson do deal in T-cell receptors

British biotech Adaptimmune Therapeutics has partnered with MD Anderson Cancer Center to develop novel adoptive T-cell therapies for use across several types of cancer. Preclinical and clinical teams from the research center will work with Adaptimmune’s SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell technology platform to find targets on solid and hematologic cancers against which to develop affinity enhanced T-cell receptors (TCRs). Source: Fierce Biotech 26/9/2016

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).